Welcome to the Shroomery Message Board! You are experiencing a small sample of what the site has to offer. Please login or register to post messages and view our exclusive members-only content. You'll gain access to additional forums, file attachments, board customizations, encrypted private messages, and much more!
Stage IV cancer patients and psilocybin - Patient Interviews
Stage IV cancer patients who suffer from anxiety may want to investigate a new research study recently approved by the Food and Drug Administration (FDA) taking place at LA BioMed. The specific aim of the study is to learn whether the psychoactive drug, psilocybin, might be effective in reducing anxiety, depression and physical pain, and therefore improving quality of life for Stage IV cancer patients.
Psilocybin is a novel agent that produces a profound alteration in your state of consciousness. To speak to a patient who went through this clinical trial, contact David Feuerherd at ********. For more information on the trial, call Charles S. Grob, MD, at *********
The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) is one of the largest independent, not-for-profit biomedical research institutes in Los Angeles County. Affiliated with both the David Geffen School of Medicine at UCLA and the Harbor-UCLA Medical Center, the Institute has an annual budget of over $67 million and currently supports more than 1,000 research studies in areas such as cardiology, emerging infections, cancer, women's health, reproductive health, vaccine research, respiratory physiology, neonatology, molecular biology, and genetics.
LA BioMed also plays a pivotal role in the training of young physician ? scientists and scientists-to-be and is active in promoting the health and well being of nearby communities through community service programs that meet a variety of social and medical needs.
Contact: David Feuerherd
firstname.lastname@example.org **********(LA BioMed)Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center